Clinical trial
A Study of Avastin (Bevacizumab) in Combination With Herceptin…
NCT00391092 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00391092 |
|---|---|
| Title | A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer. |
| Official title | A Randomized, Open-label Study to Compare the Effect of First-line Treatment With Avastin in Combination With Herceptin/Docetaxel and Herceptin/Docetaxel Alone on Progression-free Survival in Patients With HER2 Positive Locally Recurrent or Metastatic Breast Cancer. |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | bevacizumab [Avastin], Docetaxel, Herceptin |
| Enrollment | 424 |
| Start date | Sep 1, 2006 |
| Primary completion | Aug 1, 2014 |
| Completion | Aug 1, 2014 |
| First posted | Oct 23, 2006 |
| Last update posted | Aug 28, 2015 |
| Countries | Argentina, Australia, Austria, Bosnia and Herzegovina, Brazil, Canada, Czechia, France, Italy, Mexico, Romania, Russia and 4 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: